“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next cycle of negotiations will continue to strengthen Medicare for generations to come," Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, said in the news release.

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.